Glaxosmithkline Pharmaceuticals
BSE: 500660 | NSE: GLAXO | ISIN: INE159A01016 | SECTOR: Biotechnology & DrugsOpen
1,696.05High
1,724.95Low
1,686.00Prev Close
1,695.95P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
286.40BVolume
7.57KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
1,691.50Ask
-
Company Description
- Biotechnology & Drugs
BSE
500660NSE
GLAXOISIN
INE159A01016
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
Company Officers
Juby Chandy
Chief Financial Officer, Whole Time DirectorChinmay Sharma
Executive Vice President of Human ResourcesS. Choudhary
Executive Vice President - Regulatory AffairsRansom D'Souza
Executive Vice President - Communications and Government AffairsRashmi Hegde
Executive Vice President - Medical AffairsShourov Mukherjee
Executive Vice President - Adult VaccinesAmit Pandey
Executive Vice President - LegalUpendra Singh
Executive Vice President - General MedicinesAbhinav Kashyap
Vice President - TechnologyRitesh Manchanda
Vice President - Customer Supply Chain